Swiss pharmaceutical giant Vifor, which is speculated to be a takeover target of CSL, has a strong presence in Australia and is in the process of developing a range of new treatments for kidney disease.
Media speculation was widespread late last week that CSL was in advanced talks with Vifor Pharma about a $ 10 billion takeover of the company. Former CSL board member Abbas Hussain joined Vifor as CEO in the middle of this year.
Both companies moved to downplay the reports of an acquisition, with CSL saying it regularly assesses market opportunities.
“There is no assurance that any transaction will be the result of CSL’s consideration of such options and, if a transaction occurs, when such a transaction would take place,” the company told ASX.
Vifor said it was in regular talks with other market participants and could not comment on any deals.
An acquisition of the company would give CSL access to its suite of iron deficiency products as well as its portfolio of products to help treat patients with kidney disease.
Vifors’ accounts suggest that it has recently been successful in Australia.
Its report for the first half of 2021 revealed net sales of its core product Ferinject increased by more than 22 percent to 320 million francs ($ 380.2 million) for the half year.
“Overall strong market recovery was led by major European markets as well as Australia and New Zealand,” the company said.